grantGrants.gov

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Organization National Institutes of HealthPosted 22 Nov 2024Deadline 19 Nov 2026
HHS-NIH1193.242synopsis
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Explore more

🏷 More HHS-NIH11 opportunities🏷 More 93.242 opportunities🏷 More synopsis opportunities🏢 All Grants.gov opportunities

Full Description

Opportunity Number: PAR-25-226 Document Type: synopsis CFDA Numbers: 93.242

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →